CN115515573A - 用于治疗再通疗法之后再灌注损伤或出血的组合物和方法 - Google Patents

用于治疗再通疗法之后再灌注损伤或出血的组合物和方法 Download PDF

Info

Publication number
CN115515573A
CN115515573A CN202180032761.3A CN202180032761A CN115515573A CN 115515573 A CN115515573 A CN 115515573A CN 202180032761 A CN202180032761 A CN 202180032761A CN 115515573 A CN115515573 A CN 115515573A
Authority
CN
China
Prior art keywords
tetrafluoro
trifluoromethylbenzylamino
compound
therapy
benzoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180032761.3A
Other languages
English (en)
Chinese (zh)
Inventor
郭秉周
安春山
金京玉
赵成益
祝方猛
徐新良
詹威强
刘富鑫
元顺美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GNT Pharma Co Ltd
Original Assignee
GNT Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GNT Pharma Co Ltd filed Critical GNT Pharma Co Ltd
Publication of CN115515573A publication Critical patent/CN115515573A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180032761.3A 2020-03-11 2021-03-10 用于治疗再通疗法之后再灌注损伤或出血的组合物和方法 Pending CN115515573A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062988187P 2020-03-11 2020-03-11
US62/988,187 2020-03-11
PCT/IB2021/000136 WO2021181159A1 (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Publications (1)

Publication Number Publication Date
CN115515573A true CN115515573A (zh) 2022-12-23

Family

ID=77665492

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180032761.3A Pending CN115515573A (zh) 2020-03-11 2021-03-10 用于治疗再通疗法之后再灌注损伤或出血的组合物和方法

Country Status (12)

Country Link
US (3) US11826329B2 (https=)
EP (1) EP4117648A4 (https=)
JP (1) JP2023517566A (https=)
KR (1) KR20230010187A (https=)
CN (1) CN115515573A (https=)
AU (1) AU2021233206A1 (https=)
BR (1) BR112022018136A2 (https=)
CA (1) CA3174709A1 (https=)
CO (1) CO2022014343A2 (https=)
IL (2) IL296288B2 (https=)
MX (2) MX2022011214A (https=)
WO (1) WO2021181159A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
CN113995723B (zh) * 2020-07-27 2025-02-18 浙江普洛家园药业有限公司 一种索法地尔冻干粉针剂的制备方法及其产品和用途
KR20240142433A (ko) * 2021-12-28 2024-09-30 주식회사 지엔티파마 폐 장애를 치료하기 위한 조성물 및 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209957A1 (en) * 2002-06-19 2004-10-21 Byoung-Joo Gwag Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
WO2006126825A1 (en) * 2005-05-23 2006-11-30 Choongwae Pharma Corporation Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
KR20090113424A (ko) * 2008-04-28 2009-11-02 주식회사 뉴로테크 재관류 손상의 치료 또는 예방용 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100522188B1 (ko) * 2003-01-20 2005-10-18 주식회사 뉴로테크 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법
CN101180263B (zh) 2005-05-25 2011-11-02 株式会社中外制药 取代四氟苄基苯胺化合物及其药学可接受的盐的制备方法
CN102617383A (zh) 2012-03-20 2012-08-01 横店集团家园化工有限公司 索法地尔晶型、制备方法及包含索法地尔晶体的无菌粉末
JP2018502894A (ja) 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209957A1 (en) * 2002-06-19 2004-10-21 Byoung-Joo Gwag Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
WO2006126825A1 (en) * 2005-05-23 2006-11-30 Choongwae Pharma Corporation Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
KR20090113424A (ko) * 2008-04-28 2009-11-02 주식회사 뉴로테크 재관류 손상의 치료 또는 예방용 약학 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
刘春英主编: "《病理学》", 31 January 2016, 北京：中国中医药出版社, pages: 319 *
汪忠镐著: "《汪忠镐血管外科学》", 31 August 2010, 杭州：浙江科学技术出版社, pages: 911 *
田燕主编: "《药学专业知识2》", 28 February 2009, 北京：中国中医药出版社, pages: 143 *
郝晶晶主编: "《液体与其他制剂技术及设备》", 31 October 2014, 北京：中国医药科技出版社, pages: 201 - 217 *

Also Published As

Publication number Publication date
EP4117648A1 (en) 2023-01-18
EP4117648A4 (en) 2024-05-29
US12433861B2 (en) 2025-10-07
KR20230010187A (ko) 2023-01-18
IL296288B1 (en) 2024-02-01
US20260027076A1 (en) 2026-01-29
US20230390231A1 (en) 2023-12-07
JP2023517566A (ja) 2023-04-26
US20210283080A1 (en) 2021-09-16
IL309923A (en) 2024-03-01
IL296288A (en) 2022-11-01
US11826329B2 (en) 2023-11-28
WO2021181159A1 (en) 2021-09-16
BR112022018136A2 (pt) 2022-10-25
MX2022011214A (es) 2022-10-07
CO2022014343A2 (es) 2023-02-16
AU2021233206A1 (en) 2022-10-06
IL296288B2 (en) 2024-06-01
MX2025012439A (es) 2025-11-03
CA3174709A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
CN115515573A (zh) 用于治疗再通疗法之后再灌注损伤或出血的组合物和方法
ES2623503T3 (es) Composiciones para tratar náuseas y vómitos mediados centralmente
JP7232128B2 (ja) 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
KR20120022721A (ko) ＪＮＫ(ｃ-Ｊｕｎ 아미노 말단 키나제) 저해 펩티드를 이용한 망막 질환의 예방 또는 치료제, 망막 질환의 예방 또는 치료 방법, 및 이 펩티드의 용도
US20230149372A1 (en) Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
JP7470791B2 (ja) 眼疾患の予防または治療用点眼組成物
KR20150027800A (ko) 경도 인지 장해의 예방 및/또는 치료제
CN119523986A (zh) 伊马替尼在治疗中风中的用途
RU2425669C1 (ru) Средство для профилактики и лечения острого и хронического панкреатита
BR122025026201A2 (pt) Composições que compreendem o composto derivado de tetrafluorobenzila, frascos compreendendo as mesmas, uso terapêutico das mesmas e método para preparar o referido composto
KR20150051493A (ko) 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관신생 관련 질환의 예방 또는 치료용 약학적 조성물
KR20020016944A (ko) 하부 요로증 치료용 의약 조성물
US12544364B2 (en) Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
WO2016047662A1 (ja) 脳卒中の治療剤
HK40105250A (zh) 包含化合物smtp-7的药物组合物
KR101674457B1 (ko) 다사티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물
KR101869741B1 (ko) 마시티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물
WO2013044499A1 (zh) 丙型肝炎病毒免疫原性肽或其衍生物在制备预防或治疗结肠炎的药物中的应用
JP2022551373A (ja) 三環式誘導体を用いた脳卒中の治療方法
WO2022089544A1 (zh) Bzp在治疗心脑缺血性疾病中的应用
JPH0256327B2 (https=)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Republic of Korea

Address after: Gyeonggi Do, South Korea

Applicant after: Geente Pharmaceutical Co.,Ltd.

Address before: Gyeonggi Do, South Korea

Applicant before: GNT Pharmaceutical Co.,Ltd.

Country or region before: Republic of Korea

CB02 Change of applicant information